Technology

We're utilizing a supercomputer to quickly scan billions of chemicals for potential medications. Without AI & ML, medication developers must speculate which compounds will be effective and painstakingly test each molecule. Our AI-driven drug discovery platform identifies better compounds before further research.

Our drug development program creates novel medicinal molecules. We employ natural compounds to develop second- and third-generation medications. These novel medications have improved safety, effectiveness, stability, dose, and adverse effects compared to natural and synthetic products. AI and ML help us save time and money by focusing on molecules with recognized medicinal value when generating novel medicines.

Mydecine's research focuses on psychedelic compounds such as psilocybin and psilocin, the active metabolite of psilocybin. Psilocin induces the psychedelic experience via interacting with the serotonin receptor 5-HT2A, as well as other serotonin receptors. As presently supported by ongoing clinical research, developing better compounds that bind to the 5-HT2A receptor can assist patients in achieving the optimal state of consciousness and neuroplasticity required to safely and efficiently finish their psychedelic-assisted psychotherapy.

Mydecine is passionate about increasing neuroplasticity, the brain's ability to restructure its neural circuits to achieve the desired end, in order to improve treatment efficacy. This feature is unusual or missing in most drugs accessible today, and it is thought to be extremely synergistic with excellent therapeutic effects.

Natural psilocybin's variable onset time and low shelf stability make proper, scalable application for medicinal usage difficult. By utilizing AI to screen psilocybin and psilocin analogs, we can more effectively establish how these compounds need to be altered to directly address the issues of these molecules as they exist in nature.

We continue to screen billions of molecules using AI modeling, including all of our patent-pending structures. This will help us collect more data for our latest patent application spanning many families of psilocin analogs. The application offers methods to directly address increased accuracy in delivery control, duration of effect, shelf stability, and decreased adverse effects to psilocybin/psilocin, all of which are crucial for medicinal usage. We are able to address constant advancements in our second and third-generation medications thanks to our AI-driven program.

We can screen billions of molecules quickly and collect data on feasible therapeutic candidates by applying AI and ML. This information allows us to file more patent applications, enhancing the value and protection of our intellectual property portfolio.

This tool enables us to concentrate on the modifications to new compounds that are most likely to succeed. By using AI to screen drug candidates, we make our investments in the latter phases of drug development more profitable by removing prospective candidates that are likely to fail early in the process.

To summarize, Mydecine's AI and ML drug discovery program significantly increases the amount of data collected, focuses our attention on drug candidates that are most likely to succeed (saving us money in the long run), and enables us to bring safe, effective treatments to market faster than our competitors.